ABSTRACT-The effects of clonidine on substance P (SP) binding was investigated using rat brain and spinal cord membrane preparations preincubated with various concentrations of clonidine.
Substance P (SP) is believed to have a role in the transmission of noxious stimuli from peripheral to central neurons (1) . Research suggests that the descending noradrenergic system plays a role in analgesia by regulation of SP neurons (at the level of the dorsal horn), inhibition of SP release, or by alphaadrenoceptor activity (2, 3) . Another result shows that the spinal administration of epinephrine in the spinal cord transected, decerebrate animal is capable of significantly reducing noxious evoked activity in a group of neurons that have been demonstrated to be cells originating from the spinothalamic tract in the cervical cord of cats and the lumber cord in monkeys (4, 5) . These data suggest that spinally administered epinephrine may enhance anesthesia by a mechanism involving the direct action of epinephrine at the level of the dorsal horn of the spinal cord. One possible mechanism of alpha-adrenoreceptor agonist-induced pain relief includes inhibition of SP binding to its receptor. To test this hypothesis, the effect of clonidine, an alpha2-adrenergic agonist, on SP receptor binding in the brain and spinal cord membrane preparations was investigated.
All chemicals, except where noted, were obtained from Sigma Chemical Co., U.S.A. Spinal cords and brains without cerebellum from male Wistar rats (250-300g) were homogenized in 10 volumes of 0.32 M sucrose. The homogenate was centrifuged at 900 X g for 10 min, and the supernatant was removed and centrifuged at 11,500 X g for 20 min. The resulting pellet was resuspended in 50 mM Tris-HCI buffer (pH 7.4) and centrifuged at 17,000 X g three times.
[3H]SP binding assays were performed as described previously (6) . Assay buffer (10 mM MgCl2, 0.02% bovine serum albumin, 10 ,u M captopril, 10 ,u M phosphoramidon, 40 ,ug/ml bacitracin, 4 ,ug/ml leupeptin and 2 ,u g/ml chymostatin in 50 mM Tris-HC1 buffer (pH 7.4) was added to the final pellet and polytroned. The final concentration of protein was about 2.8 mg/ml. The receptor preparation was incubated with agitation for 30 min at room temperature in 350,ul aliquots with 50 pl of clonidine (Research Biochemicals, Inc., U.S.A.) (final concentra- (8) . The binding data from several experiments were analyzed together as described by Munson and Robard (9) . Statistical significance was evaluated using Student's t-test.
Interestingly, the quantity of SP binding was different between the spinal cord and brain preparations, suggesting that different receptor densities or mechanisms are involved between spinal and supraspinal tissues (Fig. 1) . Clonidine did not affect SP binding in the brain. However, clonidine at 10-4 M significantly lowered binding in the spinal cord (P < 0.02).
The data from an experiment illustrating the saturation profile of specific [3H]SP binding to spinal cord membrane preparation with and without 10-4 M clonidine are shown in Fig. 2 . Computer-assisted analysis of the data indicated a single class of binding in both preparations. Clonidine slightly altered the binding equilibrium (clonidine treatment: 1.42 ± 0.86 nM vs. control: 2.21 ± 0.73 nM), but significantly reduced the number of specific binding sites (clonidine treatment: 4.70 ± 0.44 fmol/ mg protein vs. control: 11.27 ± 1.75 fmol/mg protein, P < 0.05). The values of the control KD and Bmax reported here are in good agreement with those reported by others (10, 11) .
Clonidine at a high concentration effectively reduces SP binding in the spinal cord membrane preparation and not in the brain. The mode of clonidine inhibition of SP binding involved blockage of the specific binding sites and reducing the binding equilibrium. These experiments are the first to clearly demonstrate that clonidine affects SP binding on the spinal cord. Our data support that the 30-,ug dose of spinally administered clonidine produced a significant suppression of the mean noxiously evoked activity on the dorsal horn of spinal cord transected cats (K. Murata, personal communication). Therefore, our results suggest that clonidine-induced analgesia primarily involves spinal rather than supraspinal sites, as others have reported (12, 13) . In addition, the mechanism of clonidine analgesia involves reduction of SP binding, possibly at post-synaptic sites (14) . The potential of clonidine and other related compounds as novel non-narcotic analgesics warrants further investigation. Finally, clonidine is known to produce long lasting analgesic effects after intrathecal administration. Our finding will increase our understanding of the action of clonidine on the spinal cord level.
